AbbVie Showcases Groundbreaking Research Advancing Dermatological Care at 2026 AAD Annual Meeting AbbVie presents new clinical data related to immune-mediated skin diseases at the 2026 AAD meeting, showcasing improvements in patient outcomes.

AbbVie Showcases Groundbreaking Research Advancing Dermatological Care at 2026 AAD Annual Meeting #AbbVie #Upadacitinib #Risankizumab

Skyrizi Shows Promising Results in Phase 3 Induction Trial for Crohn's Disease Patients AbbVie's Skyrizi (risankizumab) demonstrates significant efficacy in a Phase 3 trial for Crohn's disease patients, offering new hope for treatment.

Skyrizi Shows Promising Results in Phase 3 Induction Trial for Crohn's Disease Patients #United_States #Crohn's_Disease #North_Chicago #Skyrizi #Risankizumab

Risankizumab for Heavily Pretreated CD | Docwire News Real-world data showed 60% of patients with heavily pretreated Crohn’s disease who received risankizumab achieved steroid-free clinical remission by week 12.

In a large real-world study, more than 60% of patients with #CrohnsDisease treated with #risankizumab achieved steroid-free clinical remission by week 12, and through 1 year of treatment.
#Gastroenterology #GISky #inflammatoryBowelDisease #IBDSky

Risankizumab (nombre comercial: Skyrizi®) aprobado para una nueva indicación en China

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Risankizumab #Skyrizi #AbbVie #NMPA #ChinaApproval #UlcerativeColitis #ColitisUlcerosa #IBD #Biologics #NewIndication #Risankizumab #Skyrizi

In new findings, #risankizumab was shown to be an effective and safe treatment of moderate-to-severe #psoriasis in the genital and scalp areas.

🔗View: www.hcplive.com/view...

AbbVie Seeks Approval for Pediatric Use of Risankizumab in Psoriasis Treatments AbbVie has submitted additional approval applications for Risankizumab for treating pediatric patients with psoriasis and related conditions.

AbbVie Seeks Approval for Pediatric Use of Risankizumab in Psoriasis Treatments #Japan #pediatric_psoriasis #AbbVie #Minato-ku #Risankizumab

AbbVie Secures Rare Disease Designation for Risankizumab in Pediatric Generalized Pustular Psoriasis AbbVie has obtained rare disease designation for Risankizumab to treat pediatric patients with generalized pustular psoriasis in Japan, providing hope for better options.

AbbVie Secures Rare Disease Designation for Risankizumab in Pediatric Generalized Pustular Psoriasis #Japan #Tokyo #pediatric_psoriasis #AbbVie #Risankizumab